Foresight News reports that Israeli clinical-stage immunotherapy company Enlivex Therapeutics has announced that its board has approved the allocation of up to $1 million for the purchase of Bitcoin as part of its cash management strategy. The company is listed on the NASDAQ in the United States (ticker: ENLV). CEO Oren Hershkovitz stated that with the increase in demand and acceptance of Bitcoin, along with the recent approval of Bitcoin ETFs and support from institutional investors, the company believes Bitcoin can serve as a strong asset reserve, providing value storage and inflation resistance.

#BTC #ETF